Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Ann Allergy Asthma Immunol. 2018 Feb;120(2):169-176.e1. doi: 10.1016/j.anai.2017.11.015.
Viral infection and allergy have been identified as major risk factors for exacerbation in asthma, especially in the presence of both. However, whether patients with allergic asthma are more susceptible to respiratory infections requiring antibiotics remains unknown.
To investigate allergy as a risk factor for respiratory infections requiring antibiotics based on register data from a nationwide population of patients with asthma.
A register-based prospective follow-up study was performed using the Danish prescription database. In the inclusion period from 2010 through 2011, we identified patients with allergic asthma 18 to 44 years old. Patients were investigated during the follow-up period from 2012 through 2013, depending on their prescription drug use of antiallergic medication and antibiotics. Odds ratios were adjusted for age, sex, asthma severity, education, and urban vs rural residence.
In a nationwide population we identified 60,415 patients with asthma. Based on prescriptions fillings for antiallergic medication, patients were subdivided into (1) nonallergic asthma (n = 35,334, 51.5%) and (2) allergic asthma (n = 25,081, 48.5%). Allergic asthma was associated with an increased risk of filling at least 2 antibiotic prescriptions per year compared with nonallergic asthma (odds ratio 1.28, 95% confidence interval 1.24-1.33, P < .0001). Interestingly, a subgroup analysis showed a protective effect of immunotherapy against the risk of requiring antibiotics (odds ratio 0.76, 95% confidence interval 0.66-0.87, P = .0001).
Patients with allergic asthma have an increased risk of being prescribed antibiotics for respiratory infections compared with those with nonallergic asthma. Treatment with allergen immunotherapy appears to have a protective effect against this risk.
病毒感染和过敏已被确定为哮喘恶化的主要危险因素,尤其是在同时存在这两种情况时。然而,患有过敏性哮喘的患者是否更容易发生需要抗生素治疗的呼吸道感染仍不清楚。
基于丹麦全国哮喘患者的登记数据,调查过敏作为需要抗生素治疗的呼吸道感染的危险因素。
我们进行了一项基于登记的前瞻性随访研究,使用丹麦处方数据库。在 2010 年至 2011 年的纳入期内,我们确定了 18 至 44 岁的过敏性哮喘患者。根据他们在 2012 年至 2013 年期间的处方药物使用抗变态反应药物和抗生素情况,对患者进行了随访调查。使用年龄、性别、哮喘严重程度、教育程度以及城市与农村居住情况对比值比进行了调整。
在全国范围内,我们确定了 60415 例哮喘患者。根据抗变态反应药物的处方情况,患者被分为(1)非过敏性哮喘(n=35334,51.5%)和(2)过敏性哮喘(n=25081,48.5%)。与非过敏性哮喘相比,过敏性哮喘每年至少开具 2 张抗生素处方的风险增加(比值比 1.28,95%置信区间 1.24-1.33,P<.0001)。有趣的是,亚组分析显示免疫疗法对需要抗生素的风险具有保护作用(比值比 0.76,95%置信区间 0.66-0.87,P=.0001)。
与非过敏性哮喘患者相比,患有过敏性哮喘的患者开具抗生素治疗呼吸道感染的风险增加。变应原免疫疗法的治疗似乎对这种风险具有保护作用。